Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs. However, conventional drug conjugation strategies yield heterogenous conjugates with relatively narrow therapeutic index (maximum tolerated dose/curative dose). Using leads from our previously described phage display-based method to predict suitable conjugation sites, we engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb immunoglobulin folding and assembly, or alter antigen binding. When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models. Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepared by conventional approaches. The favorable in vivo properties of the near-homogenous composition of this conjugate suggest that our strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.

Our findings suggest that the character of antigen-antibody interfaces is similar to that of other protein-protein interfaces, such as ligand-receptor interactions; in the case of VEGF, the principal difference is that the residues essential for binding to the Fab fragment are concentrated in one continuous segment of polypeptide chain, whereas those essential for binding to the receptor are distributed over four different segments and span across the dimer interface.

Highly stable sulfur/microporous carbon (S/MC) composites are prepared by vacuum infusion of sulfur vapor into microporous carbon at 600 °C, and lithium sulfide/microporous carbon (Li2S/MC) cathodes are fabricated via a novel and facile in situ lithiation strategy, i.e., spraying commercial stabilized lithium metal powder (SLMP) onto a prepared S/MC film cathode prior to the routine compressing process in cell assembly. The in situ formed Li2S/MC film cathode shows high Coulombic efficiency and long cycling stability in a conventional commercial Li-ion battery electrolyte (1.0 M LiPF6 + EC/DEC (1:1 v/v)). The reversible capacities of Li2S/MC cathodes remain about 650 mAh/g even after 900 charge/discharge cycles, and the Coulombic efficiency is close to 100% at a current density of 0.1C, which demonstrates the best electrochemical performance of Li2S/MC cathodes reported to date. Furthermore, this Li2S/MC film cathode fabricated via our in situ lithiation strategy can be coupled with a Li-free anode, such as graphite, carbon/tin alloys, or Si nanowires to form a rechargeable Li-ion cell. As the Li2S/MC cathode is paired with a commercial graphite anode, the full cell of Li2S/MC-graphite (Li2S-G) shows a stable capacity of around 600 mAh/g in 150 cycles. The Li2S/MC cathodes prepared by high-temperate sulfur infusion and SLMP prelithiation before cell assembly are ready to fit into current Li-ion batteries manufacturing processes and will pave the way to commercialize low-cost Li2S-G Li-ion batteries.

Here we describe the generation of an antibody-drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker. By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia patients, suggesting that anti-CD79b-vcMMAE could be widely used in these malignancies. By using NHL cell lines to simulate a patient population we discovered that a minimal cell-surface expression level of CD79b was required for in vitro activity. Within the subpopulation of cell lines above this minimal threshold, we found that sensitivity to free MMAE, mutation of cancer genes, and cell doubling time were poorly correlated with in vitro activity; however, the expression level of BCL-XL was correlated with reduced sensitivity to anti-CD79b-vcMMAE.

Bispecific antibodies and antibody fragments in various formats have been explored as a means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been reported with molecules such as the anti-CD19/CD3 bispecific T cell engager (BiTE) blinatumomab. However, the clinical use of many reported T cell-recruiting bispecific modalities is limited by liabilities including unfavorable pharmacokinetics, potential immunogenicity, and manufacturing challenges. We describe a B cell-targeting anti-CD20/CD3 T cell-dependent bispecific antibody (CD20-TDB), which is a full-length, humanized immunoglobulin G1 molecule with near-native antibody architecture constructed using "knobs-into-holes" technology. CD20-TDB is highly active in killing CD20-expressing B cells, including primary patient leukemia and lymphoma cells both in vitro and in vivo. In cynomolgus monkeys, CD20-TDB potently depletes B cells in peripheral blood and lymphoid tissues at a single dose of 1 mg/kg while demonstrating pharmacokinetic properties similar to those of conventional monoclonal antibodies. CD20-TDB also exhibits activity in vitro and in vivo in the presence of competing CD20-targeting antibodies. These data provide rationale for the clinical testing of CD20-TDB for the treatment of CD20-expressing B cell malignancies.